General
Preferred name
SONOLISIB
Synonyms
PX-866 ()
P&D ID
PD050457
CAS
502632-66-8
Tags
drug candidate
available
Drug indication
Glioblastoma multiforme
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110¦Á), 1.0 nM (p120¦Ã), 2.9 nM (p110¦Ä)). Antitumor activity[1][2].
DESCRIPTION Sonolisib is a small-molecule inhibitor of the alpha, gamma, and delta isoforms of phosphoinositide 3-kinase (PI3K) with potential antineoplastic activity . It is compound 4 in Zask et al. (2008) . (GtoPdb)
Cell lines
1
Organisms
0
Compound Sets
8
ChEMBL Drugs
CHEMBL411907
Clinical kinase drugs
DrugBank
DB12601
DrugMAP
DMYISJK
Guide to Pharmacology
7941
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL411907
MedChem Express Bioactive Compound Library
HY-N6775
PKIDB
External IDs
21
Properties
(calculated by RDKit )
Molecular Weight
525.24
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
4
Aromatic Ring Count
0
cLogP
3.13
TPSA
119.44
Fraction CSP3
0.52
Chiral centers
5.0
Largest ring
6.0
QED
0.29
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Targets
PIK3CA,PIK3CD,PIK3CG
Target
PI3K
PIK3CA
PIK3CB
PIK3CG
Pathway
PI3K/Akt/mTOR
Source data